KR20090048462A - 통증완화용 ｇａｂａ 접합체 - Google Patents

통증완화용 ｇａｂａ 접합체 Download PDF

Info

Publication number
KR20090048462A
KR20090048462A KR1020097003169A KR20097003169A KR20090048462A KR 20090048462 A KR20090048462 A KR 20090048462A KR 1020097003169 A KR1020097003169 A KR 1020097003169A KR 20097003169 A KR20097003169 A KR 20097003169A KR 20090048462 A KR20090048462 A KR 20090048462A
Authority
KR
South Korea
Prior art keywords
gaba
group
manufacture
acid
pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020097003169A
Other languages
English (en)
Korean (ko)
Inventor
아브라함 누델만
아다 레파엘리
이릿 길-애드
아브라함 웨즈만
Original Assignee
라모트 앳 텔-아비브 유니버시티 리미티드
바-일란 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 라모트 앳 텔-아비브 유니버시티 리미티드, 바-일란 유니버시티 filed Critical 라모트 앳 텔-아비브 유니버시티 리미티드
Publication of KR20090048462A publication Critical patent/KR20090048462A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020097003169A 2006-07-17 2007-07-17 통증완화용 ｇａｂａ 접합체 Ceased KR20090048462A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US83119506P 2006-07-17 2006-07-17
US83119206P 2006-07-17 2006-07-17
US60/831,192 2006-07-17
US60/831,195 2006-07-17

Publications (1)

Publication Number Publication Date
KR20090048462A true KR20090048462A (ko) 2009-05-13

Family

ID=38621178

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097003169A Ceased KR20090048462A (ko) 2006-07-17 2007-07-17 통증완화용 ｇａｂａ 접합체

Country Status (11)

Country Link
US (3) US8377990B2 (https=)
EP (1) EP2051735B1 (https=)
JP (1) JP5192485B2 (https=)
KR (1) KR20090048462A (https=)
CN (1) CN101511388B (https=)
AU (1) AU2007274583B2 (https=)
CA (1) CA2659521A1 (https=)
ES (1) ES2393933T3 (https=)
IL (1) IL196538A0 (https=)
MX (1) MX2009000641A (https=)
WO (2) WO2008010223A2 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544681B2 (en) 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
JP5284779B2 (ja) * 2005-06-07 2013-09-11 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド コンジュゲート化された向精神薬の新規な塩およびその調製方法
EP2051735B1 (en) 2006-07-17 2012-08-29 Ramot, at Tel Aviv University Ltd. Conjugates comprising a psychotropic drug or a gaba agonist and an organic acid and their use treating pain and other cns disorders
US20090074677A1 (en) * 2007-01-08 2009-03-19 Duke University Neuroactive steroid compositions and methods of use therefor
WO2009101616A1 (en) * 2008-02-11 2009-08-20 Ramot At Tel Aviv University Ltd. Novel conjugates for treating neurodegenerative diseases and disorders
WO2010027266A1 (en) * 2008-09-05 2010-03-11 Van De Langenberg, Hendrikus Theodorus Ardina Hubertus Means and methods for counteracting neurological disorders
CN105330603A (zh) * 2008-10-08 2016-02-17 凯飞药业公司 Gaba偶联物及其使用方法
US20100272652A1 (en) * 2009-03-26 2010-10-28 Seventh Sense Biosystems, Inc. Determination of tracers within subjects
US8141697B2 (en) * 2009-04-03 2012-03-27 Ackley Machine Corporation Method and apparatus for transporting caplets
JP5675821B2 (ja) * 2009-09-23 2015-02-25 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレート Ｔｏｌｌ様受容体モジュレーター及びその使用
WO2011070579A1 (en) * 2009-12-09 2011-06-16 Biolinerx Ltd. Methods of improving cognitive functions
WO2012038963A1 (en) 2010-09-22 2012-03-29 Ramot At Tel-Aviv University Ltd. An acid addition salt of a nortriptyline-gaba conjugate and a process of preparing same
JP5893135B2 (ja) * 2011-06-28 2016-03-23 ビボゾーン インコーポレイテッド 多重ターゲッティングの相乗効果を誘発する有効物質の組合せ及びその用途
WO2014022807A2 (en) * 2012-08-03 2014-02-06 Alumend, Llc Compositions and methods of using the compositions for plaque softening
CN113061089A (zh) 2015-09-23 2021-07-02 凯瑞康宁生物工程（武汉）有限公司 γ-羟基丁酸的前药及其组合物和用途
CN110709386B (zh) 2017-03-30 2022-06-07 凯瑞康宁生物工程（武汉）有限公司 双环杂芳基衍生物及其制备与用途
JPWO2018199174A1 (ja) * 2017-04-25 2020-02-27 生化学工業株式会社 第３級アミン化合物又はイミン化合物−ポリマーコンジュゲートとその製造方法
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
CN112424158A (zh) * 2018-05-14 2021-02-26 昌郁医药公司 萘普生和普瑞巴林的1-(酰氧基)-烷基氨基甲酸酯药物缀合物的结晶形式
ES2947089T3 (es) 2018-09-30 2023-08-01 Xwpharma Ltd Compuestos como antagonistas del receptor histamínico 3 neuronal y usos de los mismos
KR20220009954A (ko) 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법
KR102881504B1 (ko) 2019-12-20 2025-11-06 엑스더블유파마 리미티드 4-발레릴옥시부티르산의 합성 방법
CN115803017A (zh) 2020-06-18 2023-03-14 凯瑞康宁生物工程有限公司 水溶性活性药物成分的药物造粒物
AU2021292406B2 (en) 2020-06-18 2024-03-14 XWPharma Ltd. Controlled release granulations of water-soluble active pharmaceutical ingredients
CN116261451A (zh) 2020-07-24 2023-06-13 凯瑞康宁生物工程有限公司 γ-羟基丁酸衍生物的药物组合物和药物动力学
KR20230058151A (ko) 2020-10-05 2023-05-02 엑스더블유파마 리미티드 감마-하이드록시부티르산 유도체의 변형된 방출 조성물
EP4588471A3 (en) 2021-03-19 2025-09-24 XWPharma Ltd. Pharmacokinetics of combined release formulations of a gamma-hydroxybutyric acid derivative
CN114452256A (zh) * 2021-12-31 2022-05-10 浙江大学 脊髓损伤靶向药物、聚合物-疏水化合物胶束及其制备方法
CN115057865B (zh) * 2022-05-10 2023-03-31 国药集团工业有限公司 一种磷酸可待因半水合物的制备方法

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2944053A (en) 1960-07-05 Uiiilcu
US3058979A (en) 1957-05-13 1962-10-16 Smith Kline French Lab New perfluoroalkylphenothiazine derivatives
US2914528A (en) 1958-04-16 1959-11-24 Smith Kline French Lab Substituted phenothiazinyl trifluoro-methyl sulfones
NL227699A (https=) 1957-09-11 1900-01-01
US2969358A (en) 1958-12-08 1961-01-24 Searle & Co 2-chloro-10-phenothiazinecarbonylpiperazines
GB1460713A (en) 1973-06-08 1977-01-06 Kefalas As 7-fluoro substituted phenothiazines method for preparation thereof and compositions bladed rotor for a gas turbine engine
US3947579A (en) 1974-06-03 1976-03-30 Nelson Research & Development Company Method and composition for potentiating neuroleptic drugs
US3978216A (en) 1974-06-03 1976-08-31 Nelson Research & Development Company Method for treating schizophrenia and method and composition for potentiating neuroleptic drugs
US3956493A (en) 1974-10-21 1976-05-11 E. R. Squibb & Sons, Inc. Long acting tranquilizing agent
GB1540842A (en) 1976-08-25 1979-02-14 Kefalas As Phenothiazines
US5525727A (en) 1982-05-18 1996-06-11 University Of Florida Brain-specific drug delivery
JPS6072868A (ja) 1982-10-04 1985-04-24 Fujisawa Pharmaceut Co Ltd 縮合複素環誘導体およびその製造法
US4629691A (en) 1983-08-01 1986-12-16 Syntex (U.S.A.) Inc. Tricyclic antidepressant conjugates with antigens and enzymes
GB8413605D0 (en) 1984-05-29 1984-07-04 Gersan Ets Examining unfinished gemstone
US5051448A (en) 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
US4818936A (en) 1985-02-15 1989-04-04 The Broken Hill Proprietary Company Limited Method and apparatus for identifying and classifying steels
WO1986004991A1 (en) 1985-02-15 1986-08-28 The Broken Hill Proprietary Company Limited Classification of steel
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
ES8707175A1 (es) 1986-06-13 1987-07-16 Inke Sa Procedimiento para la obtencion de la n-metil-3-(p-trifluorometilfenoxi)-3-fenilpropilamina
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US5104858A (en) 1988-09-29 1992-04-14 Yale University Sensitizing multidrug resistant cells to antitumor agents
JPH02128564A (ja) 1988-11-08 1990-05-16 Nec Corp 電話付きパーソナルコンピュータ
JP2801648B2 (ja) 1989-06-14 1998-09-21 日本化薬株式会社 ６―フルオロ―４―クロマノン―２―カルボン酸アミド又はエステルの製造法
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU3244793A (en) 1991-12-09 1993-07-19 Gem International Network, Inc. Computer imaging system for gemstones
US5780590A (en) 1993-10-15 1998-07-14 Rhone-Poulenc Rorer Pharmaceuticals Inc. Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides
CA2176140A1 (en) 1993-11-24 1995-06-01 Meng Hsin Chen Indolyl group containing compounds and the use thereof to promote the release of growth hormone(s)
US5534522A (en) 1995-06-07 1996-07-09 Warner-Lambert Company (R)-(Z)-1-azabicyclo [2.2.1] heptan-3-one,O-[3-(3-methoxyphenyl)-2-propynyl] oxime maleate as a pharmaceutical agent
US5952365A (en) 1995-07-13 1999-09-14 Anormed Inc. 2- 2-(Dimethylamino)ethyl!-8,8-dipropyl-2-azaspiro 4.5!decane dimaleate
CA2162532C (en) 1995-11-09 2001-01-30 Dana J. Vanier Gemstone registration system
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
DE19622489A1 (de) 1996-06-05 1997-12-11 Hoechst Ag Salze des 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4- methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3- phenyl-propionsäure-ethylesters
US5966673A (en) 1997-01-10 1999-10-12 Diamond Technologies, Inc. System and method for computerized evaluation of gemstones
US6130221A (en) 1997-03-05 2000-10-10 Nymox Corporation Pharmaceutical agents that impede the initiation and progression of primary and secondary DMS disruptions
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US6020954A (en) 1997-12-18 2000-02-01 Imagestatistics, Inc. Method and associated apparatus for the standardized grading of gemstones
US5983238A (en) 1997-12-26 1999-11-09 Diamond Id Gemstons identification tracking and recovery system
JP4002006B2 (ja) 1998-06-29 2007-10-31 日本電信電話株式会社 色校正装置、色校正方法、および色校正プログラムを記録した記録媒体
US20010024532A1 (en) 1998-09-21 2001-09-27 Malnekoff Peter J. Automated gemstone evaluation system
US6304853B1 (en) 1998-09-21 2001-10-16 Peter J. Malnekoff Automated gemstone evaluation system
IL134664A0 (en) 1999-10-29 2001-04-30 Diamond And Jewelry 4 U Ltd System for trade in precious gemstones
US6381510B1 (en) 1999-11-19 2002-04-30 Eruggallery.Com Methods and apparatus for facilitating electronic commerce in area rugs
CA2475026A1 (en) * 1999-12-01 2001-06-07 Ucb, S.A. A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
US20010036943A1 (en) * 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
GB2379536A (en) 2000-05-23 2003-03-12 David W Hendry Jr System and method for appraising and describing jewelry and other valuable items
US20020021439A1 (en) 2000-08-07 2002-02-21 Derek Priestley Colour matching system
US7251619B2 (en) 2000-09-01 2007-07-31 Garry Ian Holloway Computer implemented method, computer program product, and system for gem evaluation
JP2005097120A (ja) 2000-10-06 2005-04-14 Mochida Pharmaceut Co Ltd ４−ヒドロキシピペリジン誘導体の非潮解性塩
WO2002028881A1 (en) * 2000-10-06 2002-04-11 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
US6569853B1 (en) 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
IL139975A0 (en) 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
US20030065586A1 (en) 2001-07-31 2003-04-03 Shaftel Keith L. Electronic commerce product pricing and selection system and method
US20030115079A1 (en) 2001-08-30 2003-06-19 Rapaport Martin M. Method of and system for ranking optimal values
US7544681B2 (en) 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
JP4521187B2 (ja) * 2001-09-27 2010-08-11 ラモト アット テル アヴィヴ ユニヴァーシティ リミテッド コンジュゲートされた抗精神病薬およびこれらの使用
US7005138B2 (en) * 2001-12-21 2006-02-28 Duramed Pharmaceuticals, Inc. Method of systematically delivering SSRIs
EP1471909A4 (en) 2002-01-16 2007-07-25 Endo Pharmaceuticals Inc PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
EP1500010A4 (en) 2002-01-25 2005-04-27 Menahem Sevdermish METHOD FOR THE DIGITAL COLOR GRADING OF JEWELS AND COMMUNICATION THEREFOR
US8046274B2 (en) 2002-01-25 2011-10-25 Menahem Sevdermish Method for digital color grading of gems and communication thereof
US20040092504A1 (en) 2002-11-12 2004-05-13 Anuthep Benja-Athon Definitive medications for treating fibromyalgia
EP1675555A4 (en) 2003-09-30 2011-03-09 Shire Llc PHARMACEUTICAL COMPOSITIONS FOR PREVENTING EXCESSIVE DOSE OR ABUSE
AR054181A1 (es) * 2004-08-26 2007-06-06 Nicholas Piramal India Ltd Prodrogas que contienen enlaces bio-divisibles. composiiciones farmaceuticas
TW200616604A (en) * 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
US7151084B2 (en) 2004-12-27 2006-12-19 Miller Landon C G Compound and method of treating neurogenic conditions using non-steroidal anti-inflammatory drug complexes
US7074775B2 (en) 2004-09-14 2006-07-11 Miller Landon C G Aminobutyramide conjugate and a pharmaceutical composition for treatment of neuronal disorders
TW200715156A (en) 2004-11-24 2007-04-16 Interdigital Tech Corp Intelligent information dissemination using a dynamic profile
JP5284779B2 (ja) 2005-06-07 2013-09-11 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド コンジュゲート化された向精神薬の新規な塩およびその調製方法
WO2007050318A2 (en) 2005-10-24 2007-05-03 Duke University Lipidomics approaches for central nervous system disorders
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
ES2573733T3 (es) 2006-05-22 2016-06-09 The Board Of Trustees Of The Leland Stanford Junior University Tratamiento farmacológico del deterioro cognitivo
EP2051735B1 (en) 2006-07-17 2012-08-29 Ramot, at Tel Aviv University Ltd. Conjugates comprising a psychotropic drug or a gaba agonist and an organic acid and their use treating pain and other cns disorders
EP2250148B1 (en) 2008-01-25 2016-08-17 XenoPort, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use
WO2009101616A1 (en) 2008-02-11 2009-08-20 Ramot At Tel Aviv University Ltd. Novel conjugates for treating neurodegenerative diseases and disorders
US8377929B2 (en) 2010-02-24 2013-02-19 Ramot At Tel-Aviv University Ltd. Crystalline forms of the tri-mesylate salt of perphenazine-GABA and process of producing the same

Also Published As

Publication number Publication date
US20130059910A1 (en) 2013-03-07
EP2051735B1 (en) 2012-08-29
US8222296B2 (en) 2012-07-17
WO2008010223A2 (en) 2008-01-24
WO2008010223A3 (en) 2008-03-20
MX2009000641A (es) 2009-02-12
JP2009543858A (ja) 2009-12-10
WO2008010222A2 (en) 2008-01-24
WO2008010222A3 (en) 2008-04-10
ES2393933T3 (es) 2013-01-02
US8377990B2 (en) 2013-02-19
CN101511388A (zh) 2009-08-19
US20090304584A1 (en) 2009-12-10
AU2007274583B2 (en) 2012-11-01
CA2659521A1 (en) 2008-01-24
CN101511388B (zh) 2012-10-24
AU2007274583A1 (en) 2008-01-24
US20100144869A1 (en) 2010-06-10
IL196538A0 (en) 2009-11-18
JP5192485B2 (ja) 2013-05-08
EP2051735A2 (en) 2009-04-29

Similar Documents

Publication Publication Date Title
KR20090048462A (ko) 통증완화용 ｇａｂａ 접합체
CN103025326B (zh) 治疗不安腿综合征的方法
US20170209432A1 (en) Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders
JP5881692B2 (ja) 双極性障害を治療する方法
US10905672B2 (en) Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
CA2609612C (en) Use of huperzine to treat epilepsy
JP2019527226A (ja) ヒストンアセチルトランスフェラーゼ活性化剤及び組成物並びにそれらの使用
JP2021510731A (ja) ペプチドおよびその使用
ES2337162T3 (es) N-arilbenzamidas sustituidas y compuestos relacionados para el tratamiento de enfermedades de amiloides y sinucleinopatias.
JP2025023120A (ja) ｄ－アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス
ES2989515T3 (es) Fármaco profiláctico o terapéutico para enfermedades neurodegenerativas
JPWO2007020935A1 (ja) Ｐ２ｙ１２受容体および／またはｐ２ｙ１４受容体ブロッカーを含有してなる疼痛治療剤
HK40093852A (zh) 阿片类物质和n-酰基乙醇胺的组合
HK1178796B (en) Methods of treating restless legs syndrome

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20090216

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20120716

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20131025

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20140128

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20131025

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I